A 15% body weight reduction the STEP-1 semaglutide benchmark is associated with type 2 diabetes remission in 37% of treated patients, 28% reduction in hypertension medication requirements, 25% improvement in sleep apnea severity, and MASH progression reversal
Near-term opportunities exist in Liraglutide, where Biocon is the only Indian firm with EU approval so far
This allows providers to see what type of weight a patient is losing, making sure progress comes primarily from fat, not muscle
Of these hormones, GIP and GLP-1, commonly referred to as incretins, modulate postprandial glucose concentrations by inducing a rapid and strong insulinotropic effect after meal ingestion, which is blunted in patients with T2D (48) and has been widely explored as pharmaceutical target for T2D
Users are essentially participating in uncontrolled self-experimentation, a reality that informed decision-making requires acknowledging